Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing
February 13, 2019 14:07 ET
|
3-V Biosciences
HANGZHOU, China and SHAOXING, China and SAN FRANCISCO, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Ascletis Pharma Inc. (Ascletis, 1672.HK) and 3-V Biosciences, Inc. (3-V Biosciences) jointly announce today...
3-V Biosciences to Present Data at the American Association for the Study of Liver Diseases Annual Meeting 2016 in Boston, MA
November 04, 2016 05:30 ET
|
3-V Biosciences
MENLO PARK, CA--(Marketwired - Nov 4, 2016) - 3-V Biosciences, Inc., a clinical-stage pharmaceutical company developing therapeutics for liver diseases, including non-alcoholic steatohepatitis...
3-V Biosciences Presents Data at Keystone Symposia Scientific Conference
March 04, 2016 05:30 ET
|
3-V Biosciences
MENLO PARK, CA--(Marketwired - Mar 4, 2016) - 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that data from its ongoing Phase...
3-V Biosciences to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA
November 02, 2015 05:30 ET
|
3-V Biosciences
MENLO PARK, CA--(Marketwired - Nov 2, 2015) - 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present three...
3-V Biosciences to Present Data at the 18th ECCO - 40th ESMO European Cancer Congress in Vienna
September 17, 2015 05:30 ET
|
3-V Biosciences
MENLO PARK, CA--(Marketwired - Sep 17, 2015) - 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present data from...
3-V Biosciences to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 12, 2015
August 03, 2015 05:30 ET
|
3-V Biosciences
MENLO PARK, CA--(Marketwired - Aug 3, 2015) - 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it...
3-V Biosciences Provides Clinical Update on TVB-2640 at AACR Metabolism and Cancer Conference
June 09, 2015 05:30 ET
|
3-V Biosciences
MENLO PARK, CA--(Marketwired - Jun 9, 2015) - 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious...
3-V Biosciences Announces Three Poster Presentations at the 2015 AACR Annual Meeting
April 07, 2015 05:30 ET
|
3-V Biosciences
MENLO PARK, CA--(Marketwired - Apr 7, 2015) - 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious...
3-V Biosciences to Present at the Cowen and Company 35th Annual Health Care Conference on March 4, 2015
February 24, 2015 05:30 ET
|
3-V Biosciences
MENLO PARK, CA--(Marketwired - Feb 24, 2015) - 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that focus on the role of fatty acid synthase (FASN) in...
3-V Biosciences Appoints Rekha Hemrajani as Chief Financial Officer
February 19, 2015 05:30 ET
|
3-V Biosciences
MENLO PARK, CA--(Marketwired - Feb 19, 2015) - 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious...